Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
An international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified vaccinia virus Ankara RSV vaccine candidate. The company wanted to obtain proof of efficacy and additional safety data by Dec-21, (building on data from their initial “In-Human” study) before launching a global Phase III programme.